Market Overview

UPDATE: Oppenheimer Raises Gilead PT on Promising Oncology Pipeline

Share:
Related GILD
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
15 Biggest Mid-Day Losers For Tuesday
Healthcare ratings roundup - upgrades/downgrades (Seeking Alpha)

Oppenheimer analyst David Ferreiro published a report Wednesday that maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and increased the price target from $45 to $50.

Ferreiro wrote, "We reviewed GILD's oncology pipeline, focusing on lead candidates idelalisib (PI3K inhibitor) for NHL/CLL and CYT387 (JAK inhibitor) for myelofibrosis. Based on their MoAs and favorable ph.I/II datasets, we see a high probability of ph.III success for these compounds. Although both face significant competition, we believe little to no value is priced into shares for these compounds. We are now including very conservative base-case estimates for idelalisib/CYT387, with room for upside potential. Although ph.III readouts will not occur until 2014-2016, we believe value for these candidates and the overall oncology pipeline will begin to creep into shares toward year-end."

Gilead closed Wednesday at $45.90.

Latest Ratings for GILD

DateFirmActionFromTo
Jul 2016NeedhamDowngradesBuyHold
Jun 2016Gabelli & CoInitiates Coverage onBuy
May 2016Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Oppenheimer & Co.Analyst Color Price Target Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!